Approved BTK Inhibitor Without Covalent Bond for CLL.

Published Date: 08 Dec 2023

In a patient population that had received extensive pretreatment, pirtobrutinib response rates were as high as 72%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

2.

In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?

3.

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

4.

How Do Younger People Fare With Stool Tests for CRC Screening?

5.

AI catches one-third of interval breast cancers missed at screening


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot